Reports
Reports
The global psoriasis treatment market is witnessing steadiness, driven primarily by the increase in prevalence of psoriasis, rising awareness and advancements in biologic and targeted therapies. More number of patients are being diagnosed with psoriasis due to the overall increase in healthcare access and improved awareness, which increases the demand for effective treatment that offers long-term control of symptoms.
Biologic therapies, especially the IL-17 and IL-23 inhibitors, are currently offering highly effective treatment options are accepted by patients and care providers. However, there are key restraints including the high price of these new therapies that are limiting access in low and middle-income areas.
.webp "Psoriasis Treatment Market Revenue Growth (USD Bn)")
The major opportunities are available particularly in emerging markets as the healthcare infrastructure improves, as well as the emergence of biosimilars in conjunction with more customized forms of treatments with facilitating technology including digital health monitoring and AI diagnostics that can help identify treatment patterns simplifying affordability, access, and effectiveness of therapy. These changes are a fast-moving landscape offering an opportunity for pharmaceutical companies in gaining new ground and ultimately helping patients.
Psoriasis is an autoimmune condition that causes inflammation in skin. Symptoms of psoriasis include thick areas of discolored skin covered with scales. These thick, scaly areas are called plaques. Psoriasis is a chronic skin condition, which means it can flare up unexpectedly and there’s no cure. Psoriasis treatment market aim to stop skin cells from growing so quickly and to remove scales. Options include creams and ointments (topical therapy), light therapy (phototherapy), and oral or injected medications.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
The increasing incidence of psoriasis is a significant driver to the growth of the psoriasis treatment market around the world. For instance, according to data published by National Center for Biotechnology Information in 2022, Psoriasis is a common chronic inflammatory disease with prevalence of 0.33%-0.6% in different races and affects around 125 million people worldwide. This growing patient pool of psoriasis, their need for more innovative treatments to manage symptoms of inflammation, red lesions, and plaques, the pressure for drugs geared toward symptom relief is increasing along with the size of the patient pool.
The increasing incidence of comorbidities including psoriatic arthritis (which occurs in 30 to 40% of psoriasis patients) will only serve to increase the need for potential therapies. Along with increased disease awareness, diagnosis, and access, the residual population seeking treatment is well defined and follow-up consultation will continue to grow.
The increasing regulatory approvals is a key driver to the psoriasis treatment industry growth as they are allowing for more advanced innovative therapies, specifically biologics and new small molecules, to be developed to provide better efficacy and safety for patients. With more innovative products such as newer interleukin inhibitors and topical products approved by regulatory agencies, patients will have a greater range of effective treatment options to treat their unmet medical needs to manage their disease.
For instance, in May 2025, Arcutis Biotherapeutics, Inc. announced the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ZORYVE (roflumilast) topical foam 0.3% for the treatment of plaque psoriasis of the scalp and body in adult and pediatric patients 12 years of age and older. ZORYVE foam is a once-daily, steroid-free topical and is now widely available as a treatment for plaque psoriasis
Furthermore, with the approval of these new therapies, there will be more new products for competition, continued development and research, and biopharmaceutical industry investment, all contributing to strong growth in the market over the forecast period.
Based on drug type, biologics is expected to be the dominating segment in psoriasis treatment market. This is due to biologics providing superior efficacy, prolonged duration/high sustained response rates, and ability to target the components of the immune system related to the inflammation processes associated with psoriasis. Evidence indicates that biologics, particularly interleukin inhibitors (IL-17 and IL-23 inhibitors), lead to improvements in skin clearance and quality of life for moderate to severe forms of psoriasis compared to systemic therapies.
The targeted mechanism of action of biologics produces fewer systemic side-effects and improved adherence to therapy. Biologics are further gaining traction in psoriasis treatment through clinical trials, regulatory approvals, as well as awareness of biologics among healthcare providers and patients. With this momentum, biologics will continue to represent the largest portion of growth in this market over the next few years.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
North America has a strong hold on the market due to its better healthcare facilities, higher prevalence of psoriasis, and emphasis on novel therapies. The U. S., in particular, dominates the North American market, accounting for a large population who have points of plaque psoriasis and psoriatic arthritis, and thus increased demand for newer advance psoriasis treatment market options.
The primary form of biologics treatment are TNF inhibitors and interleukin inhibitors, and there is also an increasing accessibility to new drugs as more are approved. Challenges exist in terms of reimbursement, regulatory processes, and competition, but overall, North America and its non-problematic advanced technologies, coupled with the many acclaims from sponsors and overall supportive research and development from the leading pharmaceutical companies solidifies North America's lead in the market.
There are also awareness initiatives, such as Psoriasis Awareness Month, which educate patients about their disease and increase treatment uptake. All these trends are creating new opportunities for patient stratification - specifically around biologics - despite the product pricing being higher and impacting patient accessibility overall. The continued development of, and access to, innovative medicines coupled with the growing focus on medical innovation would likely mitigate low product performance.
AbbVie Inc, Amgen Inc, AstraZeneca, Eli Lilly and Company, Johnson & Johnson Services, Inc., LEO Pharma A/S, Merck & Co., Inc., Novartis AG, Boehringer Ingelheim Pharmaceuticals, Inc., Arcutis Biotherapeutics, Inc., Dermavant Sciences, Inc., TIEFENBACHER GROUP, UCB S.A., Bausch Health, Sun Pharmaceutical Industries Limited, Akeso Biopharma Co., Ltd are some of the leading players operating in the global psoriasis treatment market.
Each of these players has been profiled in the psoriasis treatment market research report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
| Attribute | Detail |
|---|---|
| Size in 2024 | US$ 35.0 Bn |
| Forecast Value in 2035 | US$ 87.6 Bn |
| CAGR | 9.5% |
| Forecast Period | 2025-2035 |
| Historical Data Available for | 2020-2023 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
It was valued at US$ 35.0 Bn in 2024.
It is projected to reach US$ 87.6 Bn by the end of 2035.
Rising Prevalence of Psoriasis and Increasing regulatory approvals.
It is anticipated to grow at a CAGR of 9.5% from 2025 to 2035.
North America is expected to account for the largest share from 2025 to 2035.
AbbVie Inc, Amgen Inc, AstraZeneca, Eli Lilly and Company, Johnson & Johnson Services, Inc., LEO Pharma A/S, Merck & Co., Inc., Novartis AG, Boehringer Ingelheim Pharmaceuticals, Inc., Arcutis Biotherapeutics, Inc., Dermavant Sciences, Inc., TIEFENBACHER GROUP, UCB S.A., Bausch Health, Sun Pharmaceutical Industries Limited, Akeso Biopharma Co., and Other prominent players.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Psoriasis Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Psoriasis Treatment Market Analysis and Forecasts, 2020 to 2035
4.4.1. Market Revenue Projections (US$ Bn)
5. Key Insights
5.1. Regulatory Landscape across Key Regions / Countries
5.2. Psoriasis Treatment Market Trends
5.3. PORTER’s Five Forces Analysis
5.4. PESTEL Analysis
5.5. Key Purchase Metrics for End-users
5.6. Brand and Pricing Analysis
5.7. Treatment Algorithm
5.8. Distributors Landscape
6. Global Psoriasis Treatment Market Analysis and Forecasts, By Drug Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Drug Type, 2020 to 2035
6.3.1. Biologics
6.3.1.1. TNF Inhibitors
6.3.1.2. Interleukin Inhibitors
6.3.1.2.1. IL-17 Inhibitors
6.3.1.2.2. IL-23 Inhibitors
6.3.1.2.3. Others
6.3.2. Small Molecule Drugs
6.3.2.1. Tyrosine kinase 2 (TYK2) inhibitors
6.3.2.2. Phosphodiesterase 4 (PDE4) inhibitor
6.3.2.3. Corticosteroids
6.3.2.4. Retinoids
6.3.2.5. Calcineurin inhibitors
6.3.2.6. Others
6.4. Market Attractiveness By Drug Type
7. Global Psoriasis Treatment Market Analysis and Forecasts, By Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Type, 2020 to 2035
7.3.1. Branded
7.3.2. Generic
7.4. Market Attractiveness By Type
8. Global Psoriasis Treatment Market Analysis and Forecasts, By Types of Psoriasis
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Types of Psoriasis, 2020 to 2035
8.3.1. Plaque Psoriasis
8.3.2. Inverse Psoriasis
8.3.3. Guttate Psoriasis
8.3.4. Pustular Psoriasis
8.3.5. Others
8.4. Market Attractiveness By Types of Psoriasis
9. Global Psoriasis Treatment Market Analysis and Forecasts, By Route of Administration
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast By Route of Administration, 2020 to 2035
9.3.1. Oral
9.3.2. Topical
9.3.3. Parenteral
9.4. Market Attractiveness By Route of Administration
10. Global Psoriasis Treatment Market Analysis and Forecasts, By Distribution Channel
10.1. Introduction & Definition
10.2. Key Findings / Developments
10.3. Market Value Forecast By Distribution Channel, 2020 to 2035
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Market Attractiveness By Distribution Channel
11. Global Psoriasis Treatment Market Analysis and Forecasts, By Region
11.1. Key Findings
11.2. Market Value Forecast By Region
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness By Region
12. North America Psoriasis Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Drug Type, 2020 to 2035
12.2.1. Biologics
12.2.1.1. TNF Inhibitors
12.2.1.2. Interleukin Inhibitors
12.2.1.2.1. IL-17 Inhibitors
12.2.1.2.2. IL-23 Inhibitors
12.2.1.2.3. Others
12.2.2. Small Molecule Drugs
12.2.2.1. Tyrosine kinase 2 (TYK2) inhibitors
12.2.2.2. Phosphodiesterase 4 (PDE4) inhibitor
12.2.2.3. Corticosteroids
12.2.2.4. Retinoids
12.2.2.5. Calcineurin inhibitors
12.2.2.6. Others
12.3. Market Value Forecast By Type, 2020 to 2035
12.3.1. Branded
12.3.2. Generic
12.4. Market Value Forecast By Types of Psoriasis, 2020 to 2035
12.4.1. Plaque Psoriasis
12.4.2. Inverse Psoriasis
12.4.3. Guttate Psoriasis
12.4.4. Pustular Psoriasis
12.4.5. Others
12.5. Market Value Forecast By Route of Administration, 2020 to 2035
12.5.1. Oral
12.5.2. Topical
12.5.3. Topical
12.6. Market Value Forecast By Distribution Channel, 2020 to 2035
12.6.1. Hospital Pharmacies
12.6.2. Retail Pharmacies
12.6.3. Online Pharmacies
12.7. Market Value Forecast By Country, 2020 to 2035
12.7.1. U.S.
12.7.2. Canada
12.8. Market Attractiveness Analysis
12.8.1. By Drug Type
12.8.2. By Type
12.8.3. By Types of Psoriasis
12.8.4. By Route of Administration
12.8.5. By Distribution Channel
12.8.6. By Country
13. Europe Psoriasis Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Drug Type, 2020 to 2035
13.2.1. Biologics
13.2.1.1. TNF Inhibitors
13.2.1.2. Interleukin Inhibitors
13.2.1.2.1. IL-17 Inhibitors
13.2.1.2.2. IL-23 Inhibitors
13.2.1.2.3. Others
13.2.2. Small Molecule Drugs
13.2.2.1. Tyrosine kinase 2 (TYK2) inhibitors
13.2.2.2. Phosphodiesterase 4 (PDE4) inhibitor
13.2.2.3. Corticosteroids
13.2.2.4. Retinoids
13.2.2.5. Calcineurin inhibitors
13.2.2.6. Others
13.3. Market Value Forecast By Type, 2020 to 2035
13.3.1. Branded
13.3.2. Generic
13.4. Market Value Forecast By Types of Psoriasis, 2020 to 2035
13.4.1. Plaque Psoriasis
13.4.2. Inverse Psoriasis
13.4.3. Guttate Psoriasis
13.4.4. Pustular Psoriasis
13.4.5. Others
13.5. Market Value Forecast By Route of Administration, 2020 to 2035
13.5.1. Oral
13.5.2. Topical
13.5.3. Topical
13.6. Market Value Forecast By Distribution Channel, 2020 to 2035
13.6.1. Hospital Pharmacies
13.6.2. Retail Pharmacies
13.6.3. Online Pharmacies
13.7. Market Value Forecast By Country/Sub-region, 2020 to 2035
13.7.1. Germany
13.7.2. U.K.
13.7.3. France
13.7.4. Italy
13.7.5. Spain
13.7.6. Switzerland
13.7.7. The Netherlands
13.7.8. Rest of Europe
13.8. Market Attractiveness Analysis
13.8.1. By Drug Type
13.8.2. By Type
13.8.3. By Types of Psoriasis
13.8.4. By Route of Administration
13.8.5. By Distribution Channel
13.8.6. By Country/Sub-region
14. Asia Pacific Psoriasis Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Drug Type, 2020 to 2035
14.2.1. Biologics
14.2.1.1. TNF Inhibitors
14.2.1.2. Interleukin Inhibitors
14.2.1.2.1. IL-17 Inhibitors
14.2.1.2.2. IL-23 Inhibitors
14.2.1.2.3. Others
14.2.2. Small Molecule Drugs
14.2.2.1. Tyrosine kinase 2 (TYK2) inhibitors
14.2.2.2. Phosphodiesterase 4 (PDE4) inhibitor
14.2.2.3. Corticosteroids
14.2.2.4. Retinoids
14.2.2.5. Calcineurin inhibitors
14.2.2.6. Others
14.3. Market Value Forecast By Type, 2020 to 2035
14.3.1. Branded
14.3.2. Generic
14.4. Market Value Forecast By Types of Psoriasis, 2020 to 2035
14.4.1. Plaque Psoriasis
14.4.2. Inverse Psoriasis
14.4.3. Guttate Psoriasis
14.4.4. Pustular Psoriasis
14.4.5. Others
14.5. Market Value Forecast By Route of Administration, 2020 to 2035
14.5.1. Oral
14.5.2. Topical
14.5.3. Topical
14.6. Market Value Forecast By Distribution Channel, 2020 to 2035
14.6.1. Hospital Pharmacies
14.6.2. Retail Pharmacies
14.6.3. Online Pharmacies
14.7. Market Value Forecast By Country/Sub-region, 2020 to 2035
14.7.1. China
14.7.2. Japan
14.7.3. India
14.7.4. Australia & New Zealand
14.7.5. South Korea
14.7.6. Rest of Asia Pacific
14.8. Market Attractiveness Analysis
14.8.1. By Drug Type
14.8.2. By Type
14.8.3. By Types of Psoriasis
14.8.4. By Route of Administration
14.8.5. By Distribution Channel
14.8.6. By Country/Sub-region
15. Latin America Psoriasis Treatment Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast By Drug Type, 2020 to 2035
15.2.1. Biologics
15.2.1.1. TNF Inhibitors
15.2.1.2. Interleukin Inhibitors
15.2.1.2.1. IL-17 Inhibitors
15.2.1.2.2. IL-23 Inhibitors
15.2.1.2.3. Others
15.2.2. Small Molecule Drugs
15.2.2.1. Tyrosine kinase 2 (TYK2) inhibitors
15.2.2.2. Phosphodiesterase 4 (PDE4) inhibitor
15.2.2.3. Corticosteroids
15.2.2.4. Retinoids
15.2.2.5. Calcineurin inhibitors
15.2.2.6. Others
15.3. Market Value Forecast By Type, 2020 to 2035
15.3.1. Branded
15.3.2. Generic
15.4. Market Value Forecast By Types of Psoriasis, 2020 to 2035
15.4.1. Plaque Psoriasis
15.4.2. Inverse Psoriasis
15.4.3. Guttate Psoriasis
15.4.4. Pustular Psoriasis
15.4.5. Others
15.5. Market Value Forecast By Route of Administration, 2020 to 2035
15.5.1. Oral
15.5.2. Topical
15.5.3. Topical
15.6. Market Value Forecast By Distribution Channel, 2020 to 2035
15.6.1. Hospital Pharmacies
15.6.2. Retail Pharmacies
15.6.3. Online Pharmacies
15.7. Market Value Forecast By Country/Sub-region, 2020 to 2035
15.7.1. Brazil
15.7.2. Mexico
15.7.3. Argentina
15.7.4. Rest of Latin America
15.8. Market Attractiveness Analysis
15.8.1. By Drug Type
15.8.2. By Type
15.8.3. By Types of Psoriasis
15.8.4. By Route of Administration
15.8.5. By Distribution Channel
15.8.6. By Country/Sub-region
16. Middle East & Africa Psoriasis Treatment Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast By Drug Type, 2020 to 2035
16.2.1. Biologics
16.2.1.1. TNF Inhibitors
16.2.1.2. Interleukin Inhibitors
16.2.1.2.1. IL-17 Inhibitors
16.2.1.2.2. IL-23 Inhibitors
16.2.1.2.3. Others
16.2.2. Small Molecule Drugs
16.2.2.1. Tyrosine kinase 2 (TYK2) inhibitors
16.2.2.2. Phosphodiesterase 4 (PDE4) inhibitor
16.2.2.3. Corticosteroids
16.2.2.4. Retinoids
16.2.2.5. Calcineurin inhibitors
16.2.2.6. Others
16.3. Market Value Forecast By Type, 2020 to 2035
16.3.1. Branded
16.3.2. Generic
16.4. Market Value Forecast By Types of Psoriasis, 2020 to 2035
16.4.1. Plaque Psoriasis
16.4.2. Inverse Psoriasis
16.4.3. Guttate Psoriasis
16.4.4. Pustular Psoriasis
16.4.5. Others
16.5. Market Value Forecast By Route of Administration, 2020 to 2035
16.5.1. Oral
16.5.2. Topical
16.5.3. Topical
16.6. Market Value Forecast By Distribution Channel, 2020 to 2035
16.6.1. Hospital Pharmacies
16.6.2. Retail Pharmacies
16.6.3. Online Pharmacies
16.7. Market Value Forecast By Country/Sub-region, 2020 to 2035
16.7.1. GCC Countries
16.7.2. South Africa
16.7.3. Rest of Middle East & Africa
16.8. Market Attractiveness Analysis
16.8.1. By Drug Type
16.8.2. By Type
16.8.3. By Types of Psoriasis
16.8.4. By Route of Administration
16.8.5. By Distribution Channel
16.8.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player – Competition Matrix (By Tier and Size of companies)
17.2. Market Share Analysis By Company (2024)
17.3. Company Profiles
17.3.1. Bristol-Myers Squibb Company
17.3.1.1. Company Overview
17.3.1.2. Financial Overview
17.3.1.3. Product Portfolio
17.3.1.4. Business Strategies
17.3.1.5. Recent Developments
17.3.2. AbbVie Inc
17.3.2.1. Company Overview
17.3.2.2. Financial Overview
17.3.2.3. Product Portfolio
17.3.2.4. Business Strategies
17.3.2.5. Recent Developments
17.3.3. Amgen Inc
17.3.3.1. Company Overview
17.3.3.2. Financial Overview
17.3.3.3. Product Portfolio
17.3.3.4. Business Strategies
17.3.3.5. Recent Developments
17.3.4. AstraZeneca
17.3.4.1. Company Overview
17.3.4.2. Financial Overview
17.3.4.3. Product Portfolio
17.3.4.4. Business Strategies
17.3.4.5. Recent Developments
17.3.5. Eli Lilly and Company
17.3.5.1. Company Overview
17.3.5.2. Financial Overview
17.3.5.3. Product Portfolio
17.3.5.4. Business Strategies
17.3.5.5. Recent Developments
17.3.6. Johnson & Johnson Services, Inc.
17.3.6.1. Company Overview
17.3.6.2. Financial Overview
17.3.6.3. Product Portfolio
17.3.6.4. Business Strategies
17.3.6.5. Recent Developments
17.3.7. LEO Pharma A/S
17.3.7.1. Company Overview
17.3.7.2. Financial Overview
17.3.7.3. Product Portfolio
17.3.7.4. Business Strategies
17.3.7.5. Recent Developments
17.3.8. Merck & Co., Inc.,
17.3.8.1. Company Overview
17.3.8.2. Financial Overview
17.3.8.3. Product Portfolio
17.3.8.4. Business Strategies
17.3.8.5. Recent Developments
17.3.9. Novartis AG
17.3.9.1. Company Overview
17.3.9.2. Financial Overview
17.3.9.3. Product Portfolio
17.3.9.4. Business Strategies
17.3.9.5. Recent Developments
17.3.10. Boehringer Ingelheim Pharmaceuticals, Inc.
17.3.10.1. Company Overview
17.3.10.2. Financial Overview
17.3.10.3. Product Portfolio
17.3.10.4. Business Strategies
17.3.10.5. Recent Developments
17.3.11. Arcutis Biotherapeutics, Inc
17.3.11.1. Company Overview
17.3.11.2. Financial Overview
17.3.11.3. Product Portfolio
17.3.11.4. Business Strategies
17.3.11.5. Recent Developments
17.3.12. Dermavant Sciences, Inc.
17.3.12.1. Company Overview
17.3.12.2. Financial Overview
17.3.12.3. Product Portfolio
17.3.12.4. Business Strategies
17.3.12.5. Recent Developments
17.3.13. TIEFENBACHER GROUP
17.3.13.1. Company Overview
17.3.13.2. Financial Overview
17.3.13.3. Product Portfolio
17.3.13.4. Business Strategies
17.3.13.5. Recent Developments
17.3.14. UCB S.A.
17.3.14.1. Company Overview
17.3.14.2. Financial Overview
17.3.14.3. Product Portfolio
17.3.14.4. Business Strategies
17.3.14.5. Recent Developments
17.3.15. Bausch Health
17.3.15.1. Company Overview
17.3.15.2. Financial Overview
17.3.15.3. Product Portfolio
17.3.15.4. Business Strategies
17.3.15.5. Recent Developments
17.3.16. Sun Pharmaceutical Industries Limited
17.3.16.1. Company Overview
17.3.16.2. Financial Overview
17.3.16.3. Product Portfolio
17.3.16.4. Business Strategies
17.3.16.5. Recent Developments
17.3.17. Akeso Biopharma Co., Ltd.
17.3.17.1. Company Overview
17.3.17.2. Financial Overview
17.3.17.3. Product Portfolio
17.3.17.4. Business Strategies
17.3.17.5. Recent Developments
List of Tables
Table 01: Global Psoriasis Treatment Market Value (US$ Bn) Forecast, By Drug Type, 2020 to 2035
Table 02: Global Psoriasis Treatment Market Value (US$ Bn) Forecast, By Biologics, 2020 to 2035
Table 03: Global Psoriasis Treatment Market Value (US$ Bn) Forecast, By Small Molecule Drugs, 2020 to 2035
Table 04: Global Psoriasis Treatment Market Value (US$ Bn) Forecast, By Type, 2020 to 2035
Table 05: Global Psoriasis Treatment Market Value (US$ Bn) Forecast, By Types of Psoriasis, 2020 to 2035
Table 06: Global Psoriasis Treatment Market Value (US$ Bn) Forecast, By Route of Administration, 2020 to 2035
Table 07: Global Psoriasis Treatment Market Value (US$ Bn) Forecast, By Distribution Channel, 2020 to 2035
Table 08: Global Psoriasis Treatment Market Value (US$ Bn) Forecast, By Region, 2020 to 2035
Table 09: North America Psoriasis Treatment Market Value (US$ Bn) Forecast, by Country, 2020-2035
Table 10: North America Psoriasis Treatment Market Value (US$ Bn) Forecast, By Drug Type, 2020 to 2035
Table 11: North America Psoriasis Treatment Market Value (US$ Bn) Forecast, By Biologics, 2020 to 2035
Table 12: North America Psoriasis Treatment Market Value (US$ Bn) Forecast, By Small Molecule Drugs, 2020 to 2035
Table 13: North America Psoriasis Treatment Market Value (US$ Bn) Forecast, By Type, 2020 to 2035
Table 14: North America Psoriasis Treatment Market Value (US$ Bn) Forecast, By Types of Psoriasis, 2020 to 2035
Table 15: North America Psoriasis Treatment Market Value (US$ Bn) Forecast, By Route of Administration, 2020 to 2035
Table 16: North America Psoriasis Treatment Market Value (US$ Bn) Forecast, By Distribution Channel, 2020 to 2035
Table 17: Europe Psoriasis Treatment Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020-2035
Table 18: Europe Psoriasis Treatment Market Value (US$ Bn) Forecast, By Drug Type, 2020 to 2035
Table 19: Europe Psoriasis Treatment Market Value (US$ Bn) Forecast, By Biologics, 2020 to 2035
Table 20: Europe Psoriasis Treatment Market Value (US$ Bn) Forecast, By Small Molecule Drugs, 2020 to 2035
Table 21: Europe Psoriasis Treatment Market Value (US$ Bn) Forecast, By Type, 2020 to 2035
Table 22: Europe Psoriasis Treatment Market Value (US$ Bn) Forecast, By Types of Psoriasis, 2020 to 2035
Table 23: Europe Psoriasis Treatment Market Value (US$ Bn) Forecast, By Route of Administration, 2020 to 2035
Table 24: Europe Psoriasis Treatment Market Value (US$ Bn) Forecast, By Distribution Channel, 2020 to 2035
Table 25: Asia Pacific Psoriasis Treatment Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020-2035
Table 26: Asia Pacific Psoriasis Treatment Market Value (US$ Bn) Forecast, By Drug Type, 2020 to 2035
Table 27: Asia Pacific Psoriasis Treatment Market Value (US$ Bn) Forecast, By Biologics, 2020 to 2035
Table 28: Asia Pacific Psoriasis Treatment Market Value (US$ Bn) Forecast, By Small Molecule Drugs, 2020 to 2035
Table 29: Asia Pacific Psoriasis Treatment Market Value (US$ Bn) Forecast, By Type, 2020 to 2035
Table 30: Asia Pacific Psoriasis Treatment Market Value (US$ Bn) Forecast, By Types of Psoriasis, 2020 to 2035
Table 31: Asia Pacific Psoriasis Treatment Market Value (US$ Bn) Forecast, By Route of Administration, 2020 to 2035
Table 32: Asia Pacific Psoriasis Treatment Market Value (US$ Bn) Forecast, By Distribution Channel, 2020 to 2035
Table 33: Latin America Psoriasis Treatment Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020-2035
Table 34: Latin America Psoriasis Treatment Market Value (US$ Bn) Forecast, By Drug Type, 2020 to 2035
Table 35: Latin America Psoriasis Treatment Market Value (US$ Bn) Forecast, By Biologics, 2020 to 2035
Table 36: Latin America Psoriasis Treatment Market Value (US$ Bn) Forecast, By Small Molecule Drugs, 2020 to 2035
Table 37: Latin America Psoriasis Treatment Market Value (US$ Bn) Forecast, By Type, 2020 to 2035
Table 38: Latin America Psoriasis Treatment Market Value (US$ Bn) Forecast, By Types of Psoriasis, 2020 to 2035
Table 39: Latin America Psoriasis Treatment Market Value (US$ Bn) Forecast, By Route of Administration, 2020 to 2035
Table 40: Latin America Psoriasis Treatment Market Value (US$ Bn) Forecast, By Distribution Channel, 2020 to 2035
Table 41: Middle East & Africa Psoriasis Treatment Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020-2035
Table 42: Middle East & Africa Psoriasis Treatment Market Value (US$ Bn) Forecast, By Drug Type, 2020 to 2035
Table 43: Middle East & Africa Psoriasis Treatment Market Value (US$ Bn) Forecast, By Biologics, 2020 to 2035
Table 44: Middle East & Africa Psoriasis Treatment Market Value (US$ Bn) Forecast, By Small Molecule Drugs, 2020 to 2035
Table 45: Middle East & Africa Psoriasis Treatment Market Value (US$ Bn) Forecast, By Type, 2020 to 2035
Table 46: Middle East & Africa Psoriasis Treatment Market Value (US$ Bn) Forecast, By Types of Psoriasis, 2020 to 2035
Table 47: Middle East & Africa Psoriasis Treatment Market Value (US$ Bn) Forecast, By Route of Administration, 2020 to 2035
Table 48: Middle East & Africa Psoriasis Treatment Market Value (US$ Bn) Forecast, By Distribution Channel, 2020 to 2035
List of Figures
Figure 01: Global Psoriasis Treatment Market Value Share Analysis, By Drug Type, 2024 and 2035
Figure 02: Global Psoriasis Treatment Market Attractiveness Analysis, By Drug Type, 2025 to 2035
Figure 03: Global Psoriasis Treatment Market Revenue (US$ Bn), by Biologics, 2020 to 2035
Figure 04: Global Psoriasis Treatment Market Revenue (US$ Bn), by Small Molecule Drugs, 2020 to 2035
Figure 05: Global Psoriasis Treatment Market Value Share Analysis, By Type, 2024 and 2035
Figure 06: Global Psoriasis Treatment Market Attractiveness Analysis, By Type, 2025 to 2035
Figure 07: Global Psoriasis Treatment Market Revenue (US$ Bn), by Branded, 2020 to 2035
Figure 08: Global Psoriasis Treatment Market Revenue (US$ Bn), by Generics, 2020 to 2035
Figure 09: Global Psoriasis Treatment Market Value Share Analysis, By Types of Psoriasis, 2024 and 2035
Figure 10: Global Psoriasis Treatment Market Attractiveness Analysis, By Types of Psoriasis, 2025 to 2035
Figure 11: Global Psoriasis Treatment Market Revenue (US$ Bn), by Plaque Psoriasis, 2020 to 2035
Figure 12: Global Psoriasis Treatment Market Revenue (US$ Bn), by Inverse Psoriasis, 2020 to 2035
Figure 13: Global Psoriasis Treatment Market Revenue (US$ Bn), by Guttate Psoriasis, 2020 to 2035
Figure 14: Global Psoriasis Treatment Market Revenue (US$ Bn), by Pustular Psoriasis, 2020 to 2035
Figure 15: Global Psoriasis Treatment Market Revenue (US$ Bn), by Others, 2020 to 2035
Figure 16: Global Psoriasis Treatment Market Value Share Analysis, By Route of Administration, 2024 and 2035
Figure 17: Global Psoriasis Treatment Market Attractiveness Analysis, By Route of Administration, 2025 to 2035
Figure 18: Global Psoriasis Treatment Market Revenue (US$ Bn), by Oral, 2020 to 2035
Figure 19: Global Psoriasis Treatment Market Revenue (US$ Bn), by Topical, 2020 to 2035
Figure 20: Global Psoriasis Treatment Market Revenue (US$ Bn), by Parenteral, 2020 to 2035
Figure 21: Global Psoriasis Treatment Market Value Share Analysis, By Distribution Channel, 2024 and 2035
Figure 22: Global Psoriasis Treatment Market Attractiveness Analysis, By Distribution Channel, 2025 to 2035
Figure 23: Global Psoriasis Treatment Market Revenue (US$ Bn), by Hospital Pharmacies, 2020 to 2035
Figure 24: Global Psoriasis Treatment Market Revenue (US$ Bn), by Retail Pharmacies, 2020 to 2035
Figure 25: Global Psoriasis Treatment Market Revenue (US$ Bn), by Online Pharmacies, 2020 to 2035
Figure 26: Global Psoriasis Treatment Market Value Share Analysis, By Region, 2024 and 2035
Figure 27: Global Psoriasis Treatment Market Attractiveness Analysis, By Region, 2025 to 2035
Figure 28: North America Psoriasis Treatment Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 29: North America Psoriasis Treatment Market Value Share Analysis, by Country, 2024 and 2035
Figure 30: North America Psoriasis Treatment Market Attractiveness Analysis, by Country, 2025 to 2035
Figure 31: North America Psoriasis Treatment Market Value Share Analysis, By Drug Type, 2024 and 2035
Figure 32: North America Psoriasis Treatment Market Attractiveness Analysis, By Drug Type, 2025 to 2035
Figure 33: North America Psoriasis Treatment Market Value Share Analysis, By Type, 2024 and 2035
Figure 34: North America Psoriasis Treatment Market Attractiveness Analysis, By Type, 2025 to 2035
Figure 35: North America Psoriasis Treatment Market Value Share Analysis, By Types of Psoriasis, 2024 and 2035
Figure 36: North America Psoriasis Treatment Market Attractiveness Analysis, By Types of Psoriasis, 2025 to 2035
Figure 37: North America Psoriasis Treatment Market Value Share Analysis, By Route of Administration, 2024 and 2035
Figure 38: North America Psoriasis Treatment Market Attractiveness Analysis, By Route of Administration, 2025 to 2035
Figure 39: North America Psoriasis Treatment Market Value Share Analysis, By Distribution Channel, 2024 and 2035
Figure 40: North America Psoriasis Treatment Market Attractiveness Analysis, By Distribution Channel, 2025 to 2035
Figure 41: Europe Psoriasis Treatment Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 42: Europe Psoriasis Treatment Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
Figure 43: Europe Psoriasis Treatment Market Attractiveness Analysis, by Country / Sub-region, 2025 to 2035
Figure 44: Europe Psoriasis Treatment Market Value Share Analysis, By Drug Type, 2024 and 2035
Figure 45: Europe Psoriasis Treatment Market Attractiveness Analysis, By Drug Type, 2025 to 2035
Figure 46: Europe Psoriasis Treatment Market Value Share Analysis, By Type, 2024 and 2035
Figure 47: Europe Psoriasis Treatment Market Attractiveness Analysis, By Type, 2025 to 2035
Figure 48: Europe Psoriasis Treatment Market Value Share Analysis, By Types of Psoriasis, 2024 and 2035
Figure 49: Europe Psoriasis Treatment Market Attractiveness Analysis, By Types of Psoriasis, 2025 to 2035
Figure 50: Europe Psoriasis Treatment Market Value Share Analysis, By Route of Administration, 2024 and 2035
Figure 51: Europe Psoriasis Treatment Market Attractiveness Analysis, By Route of Administration, 2025 to 2035
Figure 52: Europe Psoriasis Treatment Market Value Share Analysis, By Distribution Channel, 2024 and 2035
Figure 53: Europe Psoriasis Treatment Market Attractiveness Analysis, By Distribution Channel, 2025 to 2035
Figure 54: Asia Pacific Psoriasis Treatment Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 55: Asia Pacific Psoriasis Treatment Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
Figure 56: Asia Pacific Psoriasis Treatment Market Attractiveness Analysis, by Country / Sub-region, 2025 to 2035
Figure 57: Asia Pacific Psoriasis Treatment Market Value Share Analysis, By Drug Type, 2024 and 2035
Figure 58: Asia Pacific Psoriasis Treatment Market Attractiveness Analysis, By Drug Type, 2025 to 2035
Figure 59: Asia Pacific Psoriasis Treatment Market Value Share Analysis, By Type, 2024 and 2035
Figure 60: Asia Pacific Psoriasis Treatment Market Attractiveness Analysis, By Type, 2025 to 2035
Figure 61: Asia Pacific Psoriasis Treatment Market Value Share Analysis, By Types of Psoriasis, 2024 and 2035
Figure 62: Asia Pacific Psoriasis Treatment Market Attractiveness Analysis, By Types of Psoriasis, 2025 to 2035
Figure 63: Asia Pacific Psoriasis Treatment Market Value Share Analysis, By Route of Administration, 2024 and 2035
Figure 64: Asia Pacific Psoriasis Treatment Market Attractiveness Analysis, By Route of Administration, 2025 to 2035
Figure 65: Asia Pacific Psoriasis Treatment Market Value Share Analysis, By Distribution Channel, 2024 and 2035
Figure 66: Asia Pacific Psoriasis Treatment Market Attractiveness Analysis, By Distribution Channel, 2025 to 2035
Figure 67: Latin America Psoriasis Treatment Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 68: Latin America Psoriasis Treatment Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
Figure 69: Latin America Psoriasis Treatment Market Attractiveness Analysis, by Country / Sub-region, 2025 to 2035
Figure 70: Latin America Psoriasis Treatment Market Value Share Analysis, By Drug Type, 2024 and 2035
Figure 71: Latin America Psoriasis Treatment Market Attractiveness Analysis, By Drug Type, 2025 to 2035
Figure 72: Latin America Psoriasis Treatment Market Value Share Analysis, By Type, 2024 and 2035
Figure 73: Latin America Psoriasis Treatment Market Attractiveness Analysis, By Type, 2025 to 2035
Figure 74: Latin America Psoriasis Treatment Market Value Share Analysis, By Types of Psoriasis, 2024 and 2035
Figure 75: Latin America Psoriasis Treatment Market Attractiveness Analysis, By Types of Psoriasis, 2025 to 2035
Figure 76: Latin America Psoriasis Treatment Market Value Share Analysis, By Route of Administration, 2024 and 2035
Figure 77: Latin America Psoriasis Treatment Market Attractiveness Analysis, By Route of Administration, 2025 to 2035
Figure 78: Latin America Psoriasis Treatment Market Value Share Analysis, By Distribution Channel, 2024 and 2035
Figure 79: Latin America Psoriasis Treatment Market Attractiveness Analysis, By Distribution Channel, 2025 to 2035
Figure 80: Middle East & Africa Psoriasis Treatment Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 81: Middle East & Africa Psoriasis Treatment Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
Figure 82: Middle East & Africa Psoriasis Treatment Market Attractiveness Analysis, by Country / Sub-region, 2025 to 2035
Figure 83: Middle East & Africa Psoriasis Treatment Market Value Share Analysis, By Drug Type, 2024 and 2035
Figure 84: Middle East & Africa Psoriasis Treatment Market Attractiveness Analysis, By Drug Type, 2025 to 2035
Figure 85: Middle East & Africa Psoriasis Treatment Market Value Share Analysis, By Type, 2024 and 2035
Figure 86: Middle East & Africa Psoriasis Treatment Market Attractiveness Analysis, By Type, 2025 to 2035
Figure 87: Middle East & Africa Psoriasis Treatment Market Value Share Analysis, By Types of Psoriasis, 2024 and 2035
Figure 88: Middle East & Africa Psoriasis Treatment Market Attractiveness Analysis, By Types of Psoriasis, 2025 to 2035
Figure 89: Middle East & Africa Psoriasis Treatment Market Value Share Analysis, By Route of Administration, 2024 and 2035
Figure 90: Middle East & Africa Psoriasis Treatment Market Attractiveness Analysis, By Route of Administration, 2025 to 2035
Figure 91: Middle East & Africa Psoriasis Treatment Market Value Share Analysis, By Distribution Channel, 2024 and 2035
Figure 92: Middle East & Africa Psoriasis Treatment Market Attractiveness Analysis, By Distribution Channel, 2025 to 2035
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Psoriasis Treatment Market